Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1358 Monotherapy or with Dalpiciclib in Advanced Breast Cancer
NCT05628870Phase 1Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-1358 in breast cancer (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Dose Limited Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Feb 2023; status: recruiting.
02
Drugs
HRS-1358
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05628870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628870.